Cargando…

Overall Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitor Luseogliflozin Versus Dipeptidyl-Peptidase 4 Inhibitors: Multicenter, Open-Label, Randomized-Controlled Trial (J-SELECT study)

INTRODUCTION: Evidence of a direct comparison between dipeptidyl-peptidase 4 inhibitors (DPP-4is) and sodium-glucose cotransporter 2 inhibitors (SGLT2is) remains lacking, and no clear treatment strategy or rationale has been established using these drugs. This study aimed to compare the overall effi...

Descripción completa

Detalles Bibliográficos
Autores principales: Sugawara, Masahiro, Fukuda, Masahiro, Sakuma, Ichiro, Wakasa, Yutaka, Funayama, Hideaki, Kondo, Akira, Itabashi, Naoki, Maruyama, Yasuyuki, Kamiyama, Takashi, Utsunomiya, Yasunori, Yamauchi, Akira, Yoshii, Hidenori, Yamada, Hirokazu, Mochizuki, Koichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10363101/
https://www.ncbi.nlm.nih.gov/pubmed/37410308
http://dx.doi.org/10.1007/s13300-023-01438-w
_version_ 1785076569017942016
author Sugawara, Masahiro
Fukuda, Masahiro
Sakuma, Ichiro
Wakasa, Yutaka
Funayama, Hideaki
Kondo, Akira
Itabashi, Naoki
Maruyama, Yasuyuki
Kamiyama, Takashi
Utsunomiya, Yasunori
Yamauchi, Akira
Yoshii, Hidenori
Yamada, Hirokazu
Mochizuki, Koichi
author_facet Sugawara, Masahiro
Fukuda, Masahiro
Sakuma, Ichiro
Wakasa, Yutaka
Funayama, Hideaki
Kondo, Akira
Itabashi, Naoki
Maruyama, Yasuyuki
Kamiyama, Takashi
Utsunomiya, Yasunori
Yamauchi, Akira
Yoshii, Hidenori
Yamada, Hirokazu
Mochizuki, Koichi
author_sort Sugawara, Masahiro
collection PubMed
description INTRODUCTION: Evidence of a direct comparison between dipeptidyl-peptidase 4 inhibitors (DPP-4is) and sodium-glucose cotransporter 2 inhibitors (SGLT2is) remains lacking, and no clear treatment strategy or rationale has been established using these drugs. This study aimed to compare the overall efficacy and safety of DPP-4is and the SGLT2i luseogliflozin in patients with type 2 diabetes mellitus (T2DM). METHODS: Patients with T2DM who had not used antidiabetic agents or who had used antidiabetic agents other than SGLT2is and DPP-4is were enrolled in the study after written informed consent had been obtained. The enrolled patients were subsequently randomly assigned to either the luseogliflozin or DPP-4i group and followed up for 52 weeks. The primary (composite) endpoint was the proportion of patients who showed improvement in ≥ 3 endpoints among the following five endpoints from baseline to week 52: glycated hemoglobin (HbA1c), weight, estimated glomerular filtration rate (eGFR), systolic blood pressure, and pulse rate. RESULTS: A total of 623 patients were enrolled in the study and subsequently randomized to either the luseogliflozin or DPP-4i groups. The proportion of patients who showed improvement in ≥ 3 endpoints at week 52 was significantly higher in the luseogliflozin group (58.9%) than in the DPP-4i group (35.0%) (p < 0.001). When stratified by body mass index (BMI) (< 25 or ≥ 25 kg/m(2)) or age (< 65 or ≥ 65 years), regardless of BMI or age, the proportion of patients who achieved the composite endpoint was significantly higher in the luseogliflozin group than in the DPP-4i group. Hepatic function and high-density lipoprotein-cholesterol were also significantly improved in the luseogliflozin group compared with the DPP-4i group. The frequency of non-serious/serious adverse events did not differ between the groups. CONCLUSION: This study showed the overall efficacy of luseogliflozin compared with DPP-4is over the mid/long term, regardless of BMI or age. The results suggest the importance of assessing multiple aspects regarding the effects of diabetes management. TRIAL REGISTRATION NUMBER: jRCTs031180241. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s13300-023-01438-w.
format Online
Article
Text
id pubmed-10363101
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-103631012023-07-24 Overall Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitor Luseogliflozin Versus Dipeptidyl-Peptidase 4 Inhibitors: Multicenter, Open-Label, Randomized-Controlled Trial (J-SELECT study) Sugawara, Masahiro Fukuda, Masahiro Sakuma, Ichiro Wakasa, Yutaka Funayama, Hideaki Kondo, Akira Itabashi, Naoki Maruyama, Yasuyuki Kamiyama, Takashi Utsunomiya, Yasunori Yamauchi, Akira Yoshii, Hidenori Yamada, Hirokazu Mochizuki, Koichi Diabetes Ther Original Research INTRODUCTION: Evidence of a direct comparison between dipeptidyl-peptidase 4 inhibitors (DPP-4is) and sodium-glucose cotransporter 2 inhibitors (SGLT2is) remains lacking, and no clear treatment strategy or rationale has been established using these drugs. This study aimed to compare the overall efficacy and safety of DPP-4is and the SGLT2i luseogliflozin in patients with type 2 diabetes mellitus (T2DM). METHODS: Patients with T2DM who had not used antidiabetic agents or who had used antidiabetic agents other than SGLT2is and DPP-4is were enrolled in the study after written informed consent had been obtained. The enrolled patients were subsequently randomly assigned to either the luseogliflozin or DPP-4i group and followed up for 52 weeks. The primary (composite) endpoint was the proportion of patients who showed improvement in ≥ 3 endpoints among the following five endpoints from baseline to week 52: glycated hemoglobin (HbA1c), weight, estimated glomerular filtration rate (eGFR), systolic blood pressure, and pulse rate. RESULTS: A total of 623 patients were enrolled in the study and subsequently randomized to either the luseogliflozin or DPP-4i groups. The proportion of patients who showed improvement in ≥ 3 endpoints at week 52 was significantly higher in the luseogliflozin group (58.9%) than in the DPP-4i group (35.0%) (p < 0.001). When stratified by body mass index (BMI) (< 25 or ≥ 25 kg/m(2)) or age (< 65 or ≥ 65 years), regardless of BMI or age, the proportion of patients who achieved the composite endpoint was significantly higher in the luseogliflozin group than in the DPP-4i group. Hepatic function and high-density lipoprotein-cholesterol were also significantly improved in the luseogliflozin group compared with the DPP-4i group. The frequency of non-serious/serious adverse events did not differ between the groups. CONCLUSION: This study showed the overall efficacy of luseogliflozin compared with DPP-4is over the mid/long term, regardless of BMI or age. The results suggest the importance of assessing multiple aspects regarding the effects of diabetes management. TRIAL REGISTRATION NUMBER: jRCTs031180241. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s13300-023-01438-w. Springer Healthcare 2023-07-06 2023-09 /pmc/articles/PMC10363101/ /pubmed/37410308 http://dx.doi.org/10.1007/s13300-023-01438-w Text en © The Author(s) 2023, corrected publication 2023 https://creativecommons.org/licenses/by-nc/4.0/Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Original Research
Sugawara, Masahiro
Fukuda, Masahiro
Sakuma, Ichiro
Wakasa, Yutaka
Funayama, Hideaki
Kondo, Akira
Itabashi, Naoki
Maruyama, Yasuyuki
Kamiyama, Takashi
Utsunomiya, Yasunori
Yamauchi, Akira
Yoshii, Hidenori
Yamada, Hirokazu
Mochizuki, Koichi
Overall Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitor Luseogliflozin Versus Dipeptidyl-Peptidase 4 Inhibitors: Multicenter, Open-Label, Randomized-Controlled Trial (J-SELECT study)
title Overall Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitor Luseogliflozin Versus Dipeptidyl-Peptidase 4 Inhibitors: Multicenter, Open-Label, Randomized-Controlled Trial (J-SELECT study)
title_full Overall Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitor Luseogliflozin Versus Dipeptidyl-Peptidase 4 Inhibitors: Multicenter, Open-Label, Randomized-Controlled Trial (J-SELECT study)
title_fullStr Overall Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitor Luseogliflozin Versus Dipeptidyl-Peptidase 4 Inhibitors: Multicenter, Open-Label, Randomized-Controlled Trial (J-SELECT study)
title_full_unstemmed Overall Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitor Luseogliflozin Versus Dipeptidyl-Peptidase 4 Inhibitors: Multicenter, Open-Label, Randomized-Controlled Trial (J-SELECT study)
title_short Overall Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitor Luseogliflozin Versus Dipeptidyl-Peptidase 4 Inhibitors: Multicenter, Open-Label, Randomized-Controlled Trial (J-SELECT study)
title_sort overall efficacy and safety of sodium-glucose cotransporter 2 inhibitor luseogliflozin versus dipeptidyl-peptidase 4 inhibitors: multicenter, open-label, randomized-controlled trial (j-select study)
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10363101/
https://www.ncbi.nlm.nih.gov/pubmed/37410308
http://dx.doi.org/10.1007/s13300-023-01438-w
work_keys_str_mv AT sugawaramasahiro overallefficacyandsafetyofsodiumglucosecotransporter2inhibitorluseogliflozinversusdipeptidylpeptidase4inhibitorsmulticenteropenlabelrandomizedcontrolledtrialjselectstudy
AT fukudamasahiro overallefficacyandsafetyofsodiumglucosecotransporter2inhibitorluseogliflozinversusdipeptidylpeptidase4inhibitorsmulticenteropenlabelrandomizedcontrolledtrialjselectstudy
AT sakumaichiro overallefficacyandsafetyofsodiumglucosecotransporter2inhibitorluseogliflozinversusdipeptidylpeptidase4inhibitorsmulticenteropenlabelrandomizedcontrolledtrialjselectstudy
AT wakasayutaka overallefficacyandsafetyofsodiumglucosecotransporter2inhibitorluseogliflozinversusdipeptidylpeptidase4inhibitorsmulticenteropenlabelrandomizedcontrolledtrialjselectstudy
AT funayamahideaki overallefficacyandsafetyofsodiumglucosecotransporter2inhibitorluseogliflozinversusdipeptidylpeptidase4inhibitorsmulticenteropenlabelrandomizedcontrolledtrialjselectstudy
AT kondoakira overallefficacyandsafetyofsodiumglucosecotransporter2inhibitorluseogliflozinversusdipeptidylpeptidase4inhibitorsmulticenteropenlabelrandomizedcontrolledtrialjselectstudy
AT itabashinaoki overallefficacyandsafetyofsodiumglucosecotransporter2inhibitorluseogliflozinversusdipeptidylpeptidase4inhibitorsmulticenteropenlabelrandomizedcontrolledtrialjselectstudy
AT maruyamayasuyuki overallefficacyandsafetyofsodiumglucosecotransporter2inhibitorluseogliflozinversusdipeptidylpeptidase4inhibitorsmulticenteropenlabelrandomizedcontrolledtrialjselectstudy
AT kamiyamatakashi overallefficacyandsafetyofsodiumglucosecotransporter2inhibitorluseogliflozinversusdipeptidylpeptidase4inhibitorsmulticenteropenlabelrandomizedcontrolledtrialjselectstudy
AT utsunomiyayasunori overallefficacyandsafetyofsodiumglucosecotransporter2inhibitorluseogliflozinversusdipeptidylpeptidase4inhibitorsmulticenteropenlabelrandomizedcontrolledtrialjselectstudy
AT yamauchiakira overallefficacyandsafetyofsodiumglucosecotransporter2inhibitorluseogliflozinversusdipeptidylpeptidase4inhibitorsmulticenteropenlabelrandomizedcontrolledtrialjselectstudy
AT yoshiihidenori overallefficacyandsafetyofsodiumglucosecotransporter2inhibitorluseogliflozinversusdipeptidylpeptidase4inhibitorsmulticenteropenlabelrandomizedcontrolledtrialjselectstudy
AT yamadahirokazu overallefficacyandsafetyofsodiumglucosecotransporter2inhibitorluseogliflozinversusdipeptidylpeptidase4inhibitorsmulticenteropenlabelrandomizedcontrolledtrialjselectstudy
AT mochizukikoichi overallefficacyandsafetyofsodiumglucosecotransporter2inhibitorluseogliflozinversusdipeptidylpeptidase4inhibitorsmulticenteropenlabelrandomizedcontrolledtrialjselectstudy
AT overallefficacyandsafetyofsodiumglucosecotransporter2inhibitorluseogliflozinversusdipeptidylpeptidase4inhibitorsmulticenteropenlabelrandomizedcontrolledtrialjselectstudy